Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, López-Corral L, Martin-Antonio B, Zabaleta A, Inogés S, Varea S, Rosiñol L, López-Díaz de Cerio A, Tovar N, Jiménez R, López-Parra M, Rodríguez-Lobato LG, Sánchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Pérez-Simón JA, Paiva B, Prósper F, Sáez-Peñataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldés A, et al. Among authors: moraleda jm. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. Lancet Oncol. 2023. PMID: 37414060 Free article.
[Immunotherapy with CAR-T cells in paediatric haematology-oncology].
Mirones I, Moreno L, Patiño-García A, Lizeaga G, Moraleda JM, Toribio ML, Pérez-Martínez A; Grupo de Inmunoterapia y Terapias Avanzadas de la Sociedad Española de Hematología y Oncología Pediátricas; Grupo de Inmunoterapia y Terapias Avanzadas de la Sociedad Española de Hematología y Oncología Pediátricas. Mirones I, et al. Among authors: moraleda jm. An Pediatr (Engl Ed). 2020 Jul;93(1):59.e1-59.e10. doi: 10.1016/j.anpedi.2019.12.014. Epub 2020 Feb 24. An Pediatr (Engl Ed). 2020. PMID: 32107177 Free article. Spanish.
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Medina-Herrera A, et al. Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3. Blood Cancer J. 2024. PMID: 38684670 Free PMC article. Clinical Trial.
N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study.
Español I, Leal JD, Blanquer M, García-Candel F, Heredia A, Gómez-Espuch J, González C, Montserrat J, Díaz-Carrasco MS, Martínez A, Moraleda JM. Español I, et al. Among authors: moraleda jm. Ann Hematol. 2023 Aug;102(8):2069-2075. doi: 10.1007/s00277-023-05248-9. Epub 2023 May 12. Ann Hematol. 2023. PMID: 37171598 Free PMC article.
Optimizing cryopreservation conditions for use of fucosylated human mesenchymal stromal cells in anti-inflammatory/immunomodulatory therapeutics.
Gil-Chinchilla JI, Bueno C, Martínez CM, Ferrández-Múrtula A, García-Hernández AM, Blanquer M, Molina-Molina M, Zapata AG, Sackstein R, Moraleda JM, García-Bernal D. Gil-Chinchilla JI, et al. Among authors: moraleda jm. Front Immunol. 2024 Mar 28;15:1385691. doi: 10.3389/fimmu.2024.1385691. eCollection 2024. Front Immunol. 2024. PMID: 38605955 Free PMC article.
Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma.
Oliver-Caldés A, Español-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velázquez S, Inoges S, López-Díaz de Cerio A, Cabañas V, López-Muñoz N, Rodriguez-Otero P, Reguera-Ortega JL, Moreno DF, Martínez-Cibrian N, López-Corral L, Pérez-Amill L, Martin-Antonio B, Rosinol L, Cid J, Tovar N, Saez-Peñataro J, Lopez-Parra M, Olesti E, Guillen E, Varea S, Rodríguez-Lobato LG, Battram AM, Gonzalez-Perez MS, Sanchez-Salinas A, González-Navarro A, Ortiz-Maldonado V, Delgado J, Prosper F, Juan M, Martinez-Lopez J, Moraleda JM, Mateos MV, Urbano-Ispizua A, Paiva B, Pascal M, Fernández de Larrea C. Oliver-Caldés A, et al. Among authors: moraleda jm. Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-23-3759. Online ahead of print. Clin Cancer Res. 2024. PMID: 38466644
Therapeutic effect of adipose-derived mesenchymal stem cells in a porcine model of abdominal sepsis.
Vélez-Pinto JF, Garcia-Arranz M, García-Bernal D, García Gómez-Heras S, Villarejo-Campos P, García-Hernández AM, Vega-Clemente L, Jiménez-Galanes S, Guadalajara H, Moraleda JM, García-Olmo D. Vélez-Pinto JF, et al. Among authors: moraleda jm. Stem Cell Res Ther. 2023 Dec 12;14(1):365. doi: 10.1186/s13287-023-03588-x. Stem Cell Res Ther. 2023. PMID: 38087374 Free PMC article.
229 results